Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-Stop: Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Advanced Melanoma
NCT04462406Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Feb 2021
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, pembrolizumab in melanoma, sponsored by ECOG-ACRIN Cancer Research Group. Started Feb 2021; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04462406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04462406.